Opendata, web and dolomites

PRELICAN

Treatment of liver disease and cancer prevention

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PRELICAN" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 150˙000.00

Map

 Project objective

Advanced liver disease and cancer is the only major cause of death still increasing each year. Major causes include hepatitis B and C viruses, alcohol and non-alcoholic fatty liver disease/steatohepatitis (NAFLD/NASH). A major contributing factor to the increasing incidence and mortality of liver disease is the staggering rise in obesity. The absence of effective therapeutic options for NAFLD/NASH, advanced liver disease and cancer contribute to the poor prognosis and the high cost associated with patient care. We have established a tractable and clinically relevant human cell-based model system in which viral infection, ethanol or free fatty acids induce a clinical gene expression signature robustly predicting liver disease progression and long-term HCC risk in cirrhotic patients. Using this model we identified compounds as HCC chemopreventive agents. Aiming to evaluate these compounds for future clinical development and potential commercialization we will perform proof-of-concept studies in state-of-the-art mouse models for NASH and hepatocarcinogenesis. Specifically we will assess the therapeutic effect on liver inflammation, steatosis, fibrosis and HCC development and investigate its safety in long-term administration. With the completion of this program we expect to obtain a robust proof-of-concept data package as a first- or best-in-class compound for treatment of chronic liver disease and prevention of HCC.

 Publications

year authors and title journal last update
List of publications.
2018 Mirjam B Zeisel, Punita Dhawan, Thomas F Baumert
Tight junction proteins in gastrointestinal and liver disease
published pages: gutjnl-2018-3169, ISSN: 0017-5749, DOI: 10.1136/gutjnl-2018-316906
Gut 2019-05-27
2018 Armando Andres Roca Suarez, Thomas F. Baumert, Joachim Lupberger
Beyond viral dependence: The pathological consequences of HCV-induced EGF signaling
published pages: 564-566, ISSN: 0168-8278, DOI: 10.1016/j.jhep.2018.05.033
Journal of Hepatology 69/3 2019-05-16

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRELICAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PRELICAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

SPA4AstroQIT (2019)

Broadband Quantum-Limited Parametric Amplifier for Astronomy and Quantum Information Technology

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More